RxDoctor Payments Data

John Richardson, MD

Family Medicine · Decatur, TXNPI 1659311850

Payments from drug & device makers

$2,107in general payments, 2019–2025

Across 120 payments — averaging $17.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$356
  • GSK$315
  • Sunovion Pharmaceuticals Inc.$169
  • Pfizer$131
  • Exact Sciences$131
  • Abbott$111
  • plus $895 from 22 others

What the payments were for

  • Food & beverage$2,107100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,107 in reported general payments places this provider in the 70th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$502,874
Medicare patients
1,221
Services billed
7,442

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban862$409,531
OzempicSemaglutide235$299,149
JardianceEmpagliflozin181$112,976
XareltoRivaroxaban174$106,149
TrulicityDulaglutide104$92,712
MyrbetriqMirabegron199$76,476
FarxigaDapagliflozin Propanediol88$63,873
Trelegy ElliptaFluticasone/Umeclidin/Vilanter84$59,882
MounjaroTirzepatide34$44,364
JanuviaSitagliptin Phosphate56$39,510
Tresiba Flextouch U-200Insulin Degludec41$36,290
Tresiba Flextouch U-100Insulin Degludec92$28,426
EntrestoSacubitril/Valsartan45$25,965
Potassium Chloride1,237$25,569
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog64$23,547

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$131$409,531862 claims
Novo NordiskOzempic$356$299,149235 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta$106$142,151233 claims
Lilly USA, LLCTrulicity, Mounjaro$85$137,076138 claims
Johnson & JohnsonXarelto$41$106,149174 claims
Astellas Pharma US IncMyrbetriq$88$76,476199 claims
AbbVieLinzess, Vraylar, Ubrelvy, Creon$85$66,22482 claims
GSKTrelegy Ellipta$315$59,88284 claims
NovartisEntresto$35$25,96545 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Decatur

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →